Novartis has five healthcare priorities: Neuroscience, Cardiology, Immunology, Oncology and Hematology, with strong positions in tech platforms (eg cell & gene therapies). Novartis have a strong pipeline, with more than 160 products in clinical development. Novartis rank number five in Ireland in terms of number of clinical trials2*. Please see below an overview of the therapy areas in which we are currently working to develop products. For more information on our products, please go to www.medicines.ie
Reflecting our commitment to innovation, 18.5% of pharma net sales globally is invested back into research and development, focusing on the areas of greatest patient need and scientific promise1. Watch the video to see the impact of innovation and collaboration on patients’ lives in Ireland.
Find out more about our work in Ireland and what matters to us below
Novartis Gene Therapies in Santry
Novartis Gene Therapies, is redefining the possibilities for patients and families affected by life-threatening genetic diseases through innovative gene therapies. Novartis Gene Therapies has located its European quality, distribution and logistics in North Dublin.
Novartis Commercial Operations at Elm Park
Health systems around the world, and in Ireland, are under pressure from the challenges of an aging population and managing chronic diseases. At Novartis Innovative Medicines we're working hard to address these issues and add value to the healthcare system through our range of medicines. As well as medicines, we are providing healthcare solutions “beyond the pill” that are fit for the future, for example new technologies, innovative devices, and patient-centric services. For example our Razorbill clinical trial, conceived in Ireland, but with sites across the globe, is assessing the use of artificial intelligence in reading scans of the eye in people with sight-threatening disease, in order to support treatment decisions, and improve outcomes for patients.
Novartis Global Services Center at Elm Park
The Novartis Global Service Center (NGSC) was set up in 2013. The center, one of five around the world, delivers a variety of services to Novartis globally.
NGSC is made up of two units- Novartis Business Services (NBS) and Global Drug Development (GDD). Services offered by the NBS team include Scientific and Commercial Services, IT, HR Services and Procurement. GDD manage all Novartis drug development work, employing more than 80 clinical scientists and 20 data science/artificial intelligence specialists. GDD play an important role in bringing new medicines to patients around the world.
NGSC Dublin has a deep talent pool driving innovation, standardisation and world-class service delivery. There are currently approximately 1,000 associates employed at the site with >40 nationalities speaking 29 languages. Almost half of the associates are educated to master’s degree level while 17% hold a PhD.
Technical and Chemical Operations at Novartis Ringaskiddy
Established over twenty five years ago, the Novartis Ringaskiddy campus is proud to be part of a unique pharma cluster in Cork with nine life sciences companies located in the region. Novartis Ringaskiddy is home to two Novartis organisations- Novartis Ringaskiddy Ltd (NRL) and Novartis Integrated Serivces (NIS).
Operational since 1994, NRL manufactures active pharmaceutical ingredients for a range of Immunology, cardiovascular and Oncology medicines.
IDA Ireland published a short video on Novartis Ringaskiddy.
We demonstrate our values through our actions
Novartis response to the coronavirus disease (COVID-19) pandemic
In the face of a global pandemic, Novartis has mobilized R&D capabilities, medicines, clinical trials expertise and aid, to provide support where we can. Novartis, through its employees in Dublin and Cork, is supporting the fight against COVID-19. Below are just some of the ways in which we worked to support the healthcare system in 2020.1